Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. develops, manufactures and sells regenerative medicine and tissue-innovation products for the Advanced Wound Care and Surgical & Sports Medicine markets. News about the company commonly covers product revenue by those markets, gross margin and profitability trends, and corporate updates tied to its Nasdaq-listed Class A common stock.
Company updates also focus on clinical and regulatory activity across its portfolio. Recurring subjects include PuraPly AM clinical evidence in diabetic foot ulcers, ReNu as a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis, FDA interactions, Biologics License Application activity, and coverage or payment developments affecting skin-substitute and wound-care products.
Organogenesis Holdings Inc. (Nasdaq: ORGO) reported net revenue of $61.7 million for Q1 2020, an increase of 8% from $57.1 million in Q1 2019. Advanced Wound Care products generated $51.3 million, up 7%, while Surgical & Sports Medicine products increased 13% to $10.4 million. Despite revenue growth, the company recorded a net loss of $16.3 million, compared to a $15.7 million loss a year earlier. The company withdrew its fiscal year 2020 revenue guidance due to uncertainty from the COVID-19 pandemic, prioritizing cost-saving measures.